Pharma BD Deal Intelligence
A $1.14B licensing deal that gave Travere ex-Asia rights to civorebrutinib, an oral BTK inhibitor, deepening its rare kidney disease bet alongside Filspari. Everest keeps Greater China and parts of Southeast Asia, with just $112.5M upfront against roughly $1.03B in milestones still to be earned.
Travere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases. Travere will bolster its rare kidney disease platform by licensing…
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside. Shares fell as much as 6% on Tuesday following announcement of the…
Why is Travere Therapeutics stock rallying today? Travere stock rose 3.1% in morning trading as the company secured global rights to civorebrutinib, a…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
On June 2, 2026, Travere Therapeutics entered an exclusive license and collaboration agreement with Everest Medicines for civorebrutinib (EVER001), an investigational oral covalent reversible BTK inhibitor for immune-mediated rare kidney diseases. Travere obtains rights in all countries outside Greater China and certain East/Southeast Asian markets (which Everest retains). Travere pays $112.5 million upfront and Everest is eligible for up to approximately $1.03 billion in clinical, regulatory and commercial milestones across up to five indications, plus tiered high-single-digit to double-digit royalties — total potential value of roughly $1.14 billion. A ten-year mutual non-compete on competing BTK products applies, subject to change-of-control exceptions. The asset extends Travere's rare kidney disease platform alongside Filspari.
Primary membranous nephropathy (pMN) is an antibody-mediated glomerular disease, in most cases driven by autoantibodies against the podocyte antigen PLA2R, that causes heavy proteinuria and nephrotic syndrome and can progress to kidney failure. It is one of the most common causes of nephrotic syndrome in adults. Current management relies on immunosuppression (e.g., rituximab, calcineurin inhibitors, cyclophosphamide regimens).
Civorebrutinib (EVER001) is in an ongoing Phase 1b/2a trial in pMN. Everest reported anti-PLA2R autoantibody reductions of 62.1% (low dose) and 87.3% (high dose) at week 12 with sustained proteinuria reductions through week 52 and a well-tolerated profile (presented at the 62nd ERA Congress). This is the lead, most-advanced indication.
Minimal change disease (MCD) is an immune-mediated podocytopathy and a common cause of nephrotic syndrome. Many patients are steroid-dependent or frequently relapsing, creating a need for steroid-sparing, B-cell-directed therapies.
Travere has disclosed minimal change disease as a planned development indication for civorebrutinib within the licensed program.
Focal segmental glomerulosclerosis (FSGS) is a pattern of podocyte injury and glomerular scarring producing proteinuria and frequent progression to end-stage kidney disease. Immune-mediated FSGS is a target of B-cell-directed approaches. No broadly effective disease-modifying therapy is approved; care is largely supportive plus immunosuppression.
Per the licensing agreement, Travere plans to develop civorebrutinib in immune-mediated FSGS as part of a multi-indication rare-kidney-disease program (up to five indications).
Travere Therapeutics entered an exclusive license and collaboration agreement with Everest Medicines for civorebrutinib (EVER001), an oral covalent reversible BTK inhibitor for rare immune-mediated kidney diseases, in all markets outside Greater China and certain East/Southeast Asian countries. $112.5M upfront + up to ~$1.03B milestones across up to five indications plus tiered royalties (~$1.14B total potential). Planned indications include primary membranous nephropathy, immune-mediated FSGS and minimal change disease.
Transaction between Travere Therapeutics and Everest Medicines is pending completion. Assessment will be updated upon deal close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Travere Therapeutics, Inc. / Everest Medicines Limited (this deal) | 2026 | $1.1B | 72 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
← Browse all deals · How we score deals
More: 2026 deals · Immunology deals